A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1midwayadmin2020-05-15T15:18:14+00:00
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1
M19-939 · Trial ·
Major Inclusion/Exclusion Criteria:
- On current HIV medication for at least 12 weeks
- HIV RNA <50 copies for 6 months
- CD4 >500
- Willing to undergo ART interruption